CONTEMPORARY USE OF TICAGRELOR IN THE COMMUNITY: INSIGHTS FROM THE BLUE CROSS BLUE SHIELD OF MICHIGAN CONSORTIUM REGISTRY (BMC2)  by Karve, Amrita et al.
A116
JACC March 17, 2015
Volume 65, Issue 10S
Acute Coronary Syndromes
contempoRaRy use oF ticagReloR in the community: insights FRom the blue cRoss 
blue shield oF michigan consoRtium RegistRy (bmc2)
Poster Contributions
Poster Hall B1
Saturday, March 14, 2015, 3:45 p.m.-4:30 p.m.
Session Title: ACS: Procedural and Long-Term Antithrombotic Therapy
Abstract Category: 3. Acute Coronary Syndromes: Therapy
Presentation Number: 1139-095
Authors: Amrita Karve, Milan Seth, Manoj Sharma, Thomas LaLonde, Simon Dixon, David Wohns, Hitinder Gurm, University of Michigan, 
Ann Arbor, MI, USA
background: Ticagrelor has greater anti-platelet activity than clopidogreland is approved for use in patients with acute coronary 
syndromes. There are limited data on use of ticagrelor in real world practice.
methods:  We assessed ticagrelor use in 64,590 patients undergoing PCIfrom January 2012 to January 2014 at 47 Michigan hospitals in 
the BlueCross Blue Shield of Michigan Cardiovascular Consortium (BMC2).Pre-procedural risk of major adverse events was estimated with 
BMC2 risk prediction models.
Results: The proportion of patients receiving clopidogrel, prasugrel, andticagrelor was 72% (n=46,854), 20% (n=12,596), and 8% 
(n=5,140)respectively with use of ticagrelor increasing over time (Figure). Ticagrelorwas used at 45 hospitals; use ranged from 0.5% 
to 64.9% of discharges.Patients receiving ticagrelor were older (63.6 vs. 59.4), more often female(32.9% vs. 26.7%), and were more 
likely to present with STEMI (24.4% vs.18.8%), cardiogenic shock within 24 hours (1.3% vs. 0.9%), and anginal class IV (47.8 % vs. 
43.0%) (p<0.05). Compared to prasugrel, ticagrelor was prescribed in patients with a higher predicted risk of PCIcomplications: contrast 
nephropathy (2.5% vs. 1.6%), transfusion (2.2% vs. 1.4%), and death (1.2% vs. 0.7%) (p <0.001). Nearly 20% of patients were given 
prasugrel or ticagrelor for a non-ACS indication.
conclusion:  Ticagrelor is prescribed to a higher risk population, and 1 in 5 patients discharged on ticagrelor do not have ACS.
